Global X Genomics & Biotechnology ETF (GNOM)
| Assets | $246.93M |
| NAV | $15.54 |
| Expense Ratio | 0.50% |
| PE Ratio | -11.00 |
| Shares Out | 15.89M |
| Dividend (ttm) | $0.01 |
| Dividend Yield | 0.04% |
| Ex-Dividend Date | Dec 30, 2021 |
| 1-Year Return | -37.14% |
| Volume | 43,628 |
| Open | 15.44 |
| Previous Close | 15.54 |
| Day's Range | 15.03 - 15.44 |
| 52-Week Low | 10.48 |
| 52-Week High | 25.05 |
| Beta | 1.01 |
| Holdings | 41 |
| Inception Date | Apr 5, 2019 |
About GNOM
The fund invests at least 80% of its total assets in the securities of the underlying index. The underlying index is designed to provide exposure to exchange-listed companies that are positioned to benefit from further advances in the field of genomic science and biotechnology, as well as applications thereof (collectively, Genomics & Biotechnology Companies), as defined by Solactive AG, the provider of the underlying index. The fund is non-diversified.
Top 10 Holdings
45.27% of assets| Name | Symbol | Weight |
|---|---|---|
| Beam Therapeutics | BEAM | 5.23% |
| CRISPR Therapeutics AG | CRSP | 5.15% |
| GENSCRIPT BIOTECH CORP | 1548.HK | 4.78% |
| Sarepta Therapeutics | SRPT | 4.70% |
| Natera | NTRA | 4.67% |
| Alnylam Pharmaceuticals | ALNY | 4.63% |
| Intellia Therapeutics | NTLA | 4.22% |
| BioNTech SE | BNTX | 4.16% |
| BioMarin Pharmaceutical | BMRN | 3.92% |
| Myriad Genetics | MYGN | 3.81% |
Dividends
| Ex-Dividend | Amount | Pay Date |
|---|---|---|
| Dec 30, 2021 | $0.00651 | Jan 7, 2022 |
| Dec 30, 2020 | $0.0324 | Jan 8, 2021 |
News
Top ETFs Tracking CRISPR Gene Editing
These ETFs give you exposure to CRISPR gene editing without having to pick individual stocks.
ETF Battles: ARKG Vs IDNA Vs GNOM
Join us for a triple-header to determine the best genomics biotech ETF!
Healthcare ETFs to Gain on $65-Billion Pandemic Protection Plan
The Biden administration recently offered a $65 billion plan that U.S. officials say is aimed at combating the biological threats after the COVID-19 pandemic goes away.
Snag Next-Generation Tech Exposure with This Genomics ETF
ETF investors looking to get in on the next generation of medical technology may want to give the Global X Genomics & Biotechnology ETF (GNOM) a closer look. Genomic sequencing is already playing a pivo...
Genomics ETFs Surge on a Major Breakthrough in CRISPR Study
The genomic-editing space has come under the spotlight with the release of encouraging data from a study assessing an in vivo CRISPR-based gene editing therapy candidate, NTLA-2001.
3 Biotech ETFs That Could Double Your Money by 2025 With Zero Effort
In a sector where picking individual stocks is a high-risk, high-reward strategy, the diversification of exchange-traded funds can be highly appealing.
Biotech ETFs Surge on Biogen's Alzheimer Drug Approval
The approval for Biogen's Alzheimer's disease treatment has spread strong optimism, with many investors pulling in capital to this high growth and high beta sector.
Can Global X's GNOM Be the Next Big ETF?
Genomics could be the next big thing in the biotechnology space. Similarly, the Global X Genomics & Biotechnology ETF (GNOM) could be the next big fund, and is already up 10% to start the new year.
Top-Performing Biotech ETFs Amid the COVID-19 Crisis
The coronavirus pandemic triggered a race to introduce vaccine and treatment, thereby opening up new investing opportunities in the biotech sector in 2020.
Get On Board a Growing Biotech Industry With the GNOM ETF
It's one thing to discuss the economics of investing in the biotech sector, but it's another to discuss genomics. The sub-sector of the biotech industry has seen strong growth as evidenced by the over 6...
Biotech ETFs surge on vaccine rollout, Alexion-AstraZeneca tie-up
Biotech exchange-traded funds rallied Monday as the rollout of the coronavirus vaccine across America shed a bullish light on the industry. The First Trust NYSE Arca Biotechnology Index Fund jumped 4% b...
Why You Should Invest in Genomics ETFs
Genomics ETFs have surged of late; here's why
Top Sector ETFs From Wall Street's Best Week in 3 Months
Last week was cheery for Wall Street, with the S&P 500 and Nasdaq recording their best weekly advancement since July.
Genomics ETFs Surge on Nobel Prize for Gene-Editing Pioneers
The announcement of the 2020 Nobel Prize winners for Chemistry has successfully brought investor attention to the gene-editing space.
Buy the Dip With These ETFs Under $20
The recent market rout led by the tech selloff has provided investors a great opportunity to tap the stocks under $20.
Jay Jacobs: These High-Growth ETF Themes Have Seen Triple-Digit Returns In Coronavirus Rally
Jay Jacobs, SVP and head of research and strategy at Global X ETFs, joined the podcast this week to discuss thematic investing and the new Global X Telehealth ETF (EDOC). Plus, we take a look at two ETF...
The Genomics Market is Poised for Growth Through 2025
Disruptive technology is always an interesting play for investors to consider and the genomics market is one to watch closely. According to the “Genomics Market – Growth, Trends, and Forecasts (2020-202...
